Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001209191-23-011942 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-22 | 2023-02-17 | PHIO | Lockshin Curtis | Dir | A - Grant | $0.00 | +1,500 | 3,197 | +88% | $0 |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2023-02-17 | A | A | 1,500 | $0.00 | 3,197 | D | — | — | (F1) Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. (F2) Includes shares of common stock underlying unvested restricted stock units. Effective as of 12:01 a.m. Eastern Time on January 26, 2023, the issuer effected a reverse split of its outstanding shares of common stock at a ratio of 1-for-12. |